Medicine Name: Oncovet C
Cychophosphamide 50 mg - Pills.
Package: 3 blister containing 10 pills each (30 pills).
Chemotherapy drug to canine and feline with cancer.
Use in veterinary medicine
Made in Argentina
Description: Chemotherapy for dogs and cats. Composition: Cyclophosphamide: 50 mg Excipients authorized. 166 mg c.s.p.
Action: Chemotherapy. The basic idea behind drugs of cancer chemotherapy is for them to reach areas of the body that are inaccessible to surgery and to kill only the cancer cells and leave alone the normal cells of the body. Cyclophosphamide is a member of the alkylating agent of chemotherapy, which act by binding DNA to other DNA strands or to protein in such a way that the DNA double helix strand cannot replicate. In addition to essentially tangling DNA up, cyclophosphamide generates a by-product that prevents normal DNA function.
Indications: Canine treatment with cancer (carcinomas of anal sacs, bladder carcinomas, urethral carcinomas, hemangiosarcomas, lymphomas, mast cell tumor, osteosarcomas, soft tissue sarcoma), feline cancers (mammary carcinomas, hemangiosarcomas, lymphomas, plasmacytomas, chronic lymphocytic leukemia, leukemia acute myelogenous, mast cell tumor), immunomediated canine diseases (immune-mediated hemolytic anemia, immune-mediated arthritis, immune-mediated glomerulonephritis, immune-mediated meningoencephalitis, immune-mediated pemphigus and thrombocytopenia) and feline immunomediated diseases (immune-mediated hemolytic anemia and immune-mediated arthritis). It can be administered in different treatment schemes, such as induction therapy, adjuvant, neoadjuvant, maintenance and metronomic chemotherapy.
In chemotherapy of INDUCTION, ADYUVANT, NEOADYUVANT AND MAINTENANCE the dose is 50 mg / mt2 per day, in 3 days in the week (intercalated days). This is repeated every 21 days and is called 1 cycle. Minimum dose: 10 mg / mt2 per day, in 3 days in the week (intercalated days). This is repeated every 21 days and is called 1 cycle.
Maximum dose: 300 mg / mt2 per day, in 3 days
in the week (intercalated days). This is repeated every 21 days and is called 1 cycle.
In METRONOMIC chemotherapy the dose is 12.5 mg / mt2 per day continuously. Minimum dose: 10 mg / mt2 per day. Maximum dose: 15 mg / mt2per day.
There is report the case of a canine that mistakenly consumed the equivalent of 2,303 mg / mt2 of cyclophosphamide, in 4 weeks and survived (Finlay et al., 2017).
Dose interval: It must be calculated by the veterinary oncologist, according to certain variables such as: clinical stage of the animal with cancer, histopathological study results, other complementary studies and diseases or conditions of the animal concomitantly. In chemotherapy of INDUCTION, ADYUVANT, NEOADYUVANT AND MAINTENANCE varies between 15 and 28 days.
In a METRONOMIC chemotherapy scheme, it can be administered every 24-48 hours per life, but daily evaluating that the clinical benefits in the patient are superior to the collateral effects and the progression of the oncological or immune-mediated disease.
Number of administrations: The number of cycles must be calculated by the veterinary oncologist, according to certain variables such as: clinical stage of the animal with cancer, results of the histopathological study, other complementary studies and diseases or conditions of the animal concomitantly. In chemotherapy INDUCTION, ADJUVANT, NEOADYUVANT AND MAINTENANCE vary between 4 and 8 cycles.
Therapeutic regimen: The interval and numbers of cycles should be indicated by a diplomate veterinary oncology. General rule is between 21-28 days.
Precautions to be taken before, during and after administration: Handling: Cyclophosphamide is classified as a non-aggressive cytostatic according to its tissue aggressiveness. The drug Oncovet C contains cyclophosphamide in coated tablets. The person who administers does not require protection from exposure unless the tablets are broken or fragmented. The procedures destined to a correct manipulation and elimination of the anticarcinogenic drugs should be considered. Several informative guidelines have already been published in this regard. In case of irritation during handling, it is recommended to wash with water and soap for 10-15 minutes. It is recommended that pregnant women do not handle the medication. If they are required to do so, it is recommended that they wear latex or nitrile gloves. The stool of the animal (fecal matter, urine, saliva or vomit) should also be cleaned using latex or nitrile gloves for 48 hours after the last administration. Prevention of sterile hemorrhagic cystitis: Sterile hemorrhagic cystitis is a possible side effect of cyclophosphamide, which can affect quality of life. The administration of mesna and forced diuresis are effective to avoid hemorrhagic cystitis. Dogs that received either mesna or furosemide were significantly less likely to develop sterile haemorrhagic cystitis and no significant differences were found between them, which demonstrates the efficacy and medical indication of mesna and furosemide for the prevention of sterile hemorrhagic cystitis induced by cyclophosphamide. Oncovet C must be administered directly orally. It should be used judiciously and with constant monitoring in patients with renal and / or hepatic insufficiency. It is recommended to respect the indicated indications, administration mode and posology. Do not use or store near drinks, food, medicines, household and fire products. Keep in a dry and cool place, protected from sunlight and far from the reach of children and pets. Most adverse reactions are reversible if they are detected early. When such adverse effects or reactions occur, the dose of the drug should be reduced or the treatment discontinued and the appropriate corrective measures adopted at the veterinarian's discretion. Laboratory tests: Due to the late suppression of the bone marrow blood tests should be performed weekly for a minimum of 6 weeks from the administration of the dose. Systematic controls should be carried out, complete blood count (with platelet count) 1 week after the administration of each dose and before the next dose; If the platelets are less than 50,000 / μl, stop the treatment until thrombocytopenia is resolved. Liver and kidney function tests before starting treatment and then every 3-4 weeks.
Interactions with Other Drugs: The following drug interactions have been documented or are theoretically possible in animals receiving cyclophosphamide: Allopurinol: May increase myelosuppression caused by cyclophosphamide. Cardiotoxic drugs (for example, Doxorubicin). Use cautiously when using cyclophosphamide together with other cardiotoxic agents since potentiation of this effect may occur. Chloramphenicol: May inhibit the metabolism of cyclophosphamide. Imipramine: May inhibit the metabolism of cyclophosphamide. Phenobarbital (or other barbiturates): The administration of these drugs for a long time increases the speed of the metabolism of cyclophosphamide to active metabolites through the process of microsomal enzymatic induction and increases the possibility of development of toxicity. Phenothiazines: They can inhibit the metabolism of cyclophosphamide. Potassium iodide: May inhibit the metabolism of cyclophosphamide. Succinylcholine: Metabolism can be slowed down with the resulting prolongation of effects, since cyclophosphamide can lower levels of circulating pseudocholinesterase. Diuretics derived from thiazides: May increase myelosuppression caused by cyclophosphamide. Vitamin A: It can inhibit the metabolism of cyclophosphamide. The levels of uric acid (in blood and urine) may increase after administering cyclophosphamide. The immunosuppressive properties of cyclophosphamide can cause false negative results in skin tests with a variety of antigens, including tuberculin, candida and trichophyton.
Concerns and Cautions: As with all chemotherapy agents, cyclophosphamide should not be used in pregnancy, lactation, or in animals to be used for breeding. Live vaccinations should not be given while the patient is on Cyclophospamide.